Pemetrexed Market Size Will Escalate Rapidly in the Near Future

1. Pemetrexed Market Size, Share, Trend, Pemetrexed Market Size, Share, Trend, Outlook, Future Growth Analysis And Outlook, Future Growth Analysis And Synthesis 2018 - 2026 Synthesis 2018 - 2026 Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name Alimta. In 2004, Alimta (Pemetrexed injection) was approved by FDA in combination with cisplatin as an initial treatment for patients with malignant pleural mesothelioma. In 2008, ALIMTA, in combination with cisplatin, was approved as an initial chemotherapy treatment for locally advanced or metastatic NSCLC for patients with nonsquamous histology, and in 2009, ALIMTA was approved as a maintenance therapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). Request PDF Brochure of Research Report @ Request PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/ https://www.coherentmarketinsights.com/insight/request-pdf/ 2458 2458 Market Dynamics Market Dynamics Launch of generic version of pemetrexed in key region is expected to increase affordability of pemetrexed, which in turn is expected to support global pemetrexed market growth over the forecast period. For instance, in July 2018, STADAPHARM GmbH, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe. High prevalence of non-small cell lung cancer and pleural mesothelioma is expected to rise the demand for Pemetrexed for its treatment and support global pemetrexed market growth over the forecast period. For instance, according to the data published by American Society of Clinical Oncology, in January 2018, in the U.S. around 234,030 adults (121,680 men and 112,350 women) were diagnosed with lung cancer among which non-small cell lung cancer is the most common type of lung cancer, accounting for 80% to 85% of all lung cancer diagnose.

2. North America is expected to Hold Dominant Position, Owing to High Prevalence of Non-small Cell Lung North America is expected to Hold Dominant Position, Owing to High Prevalence of Non-small Cell Lung Cancer and its High Treatment Rate in the U.S. Cancer and its High Treatment Rate in the U.S. According to Eli Lilly and Company’s annual report 2017, Alimta (pemetrexed) generated around 50% of its revenue from the U.S. Hence, North America is expected to be most conducive region for growth of the pemetrexed market, due to high prevalence of non-small cell lung cancer and high cost for its treatment. For instance, according to the data published by the American Cancer Society in 2017, lung cancer (both small cell and non-small cell) is the second most common type of cancer in U.S and around 13% of all new cancers are lung cancer. American Cancer Society also estimated that in 2019, around 228,150 new cases of lung cancer (116,440 in men and 111,710 in women) would be diagnosed in the U.S. and survival rate for non-small cell lung cancer in stage IA1 NSCLC is about 92%, stage IB NSCLC (68%), stage IIIA NSCLC (36%), stage IIIC cancers (13%), and for stage IIIC cancers (13%). Report includes chapters which deeply display the following deliverable about industry : Report includes chapters which deeply display the following deliverable about industry : • Pemetrexed Market Research Objective and Assumption • Pemetrexed Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Pemetrexed Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Pemetrexed Market, By Regions • Pemetrexed Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Pemetrexed Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Pemetrexed Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List.

3. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Pemetrexed Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Key players operating in the global pemetrexed market include Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., and others. Detailed Segmentation: Detailed Segmentation: Global Pemetrexed Market, By Strength : Global Pemetrexed Market, By Strength : 100 mg • 500 mg • Global Pemetrexed Market, By Distribution Channel: Global Pemetrexed Market, By Distribution Channel: Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • Get Full Access of This Business Report: Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/ https://www.coherentmarketinsights.com/market-insight/ pemetrexed-market-2458 pemetrexed-market-2458 About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

4. Contact Us Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: Email: sales@coherentmarketinsights.com sales@coherentmarketinsights.com